Using the short form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort

Arthritis Care and Research

Volumn 57, Issue 6, 2007, Pages 986-992

  Fernández, Mónica ^a   Alarcón, Graciela S ^a,d   McGwin Jr , Gerald ^a   Sanchez, Martha L ^a   Apte, Mandar ^a   Vilá, Luis M ^b   Reveille, John D ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c UNIVERSITY OF TEXAS   (United States)

^d 830 Faculty Office Tower ^*  (United States)

Author keywords

Damage; Health related quality of life; Mortality; SF 6D; Short form 36; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; ETHNICITY; FEMALE; HAZARD RATIO; HEALTH STATUS; HEALTH SURVEY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; SHORT FORM 36; SHORT FORM 6D; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADULT; AFRICAN AMERICANS; COHORT STUDIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS; HEALTH STATUS INDICATORS; HISPANIC AMERICANS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; UNITED STATES;

EID: 34547819677     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22908     Document Type: Article

References (48)

1. Froberg DG, Kane RL. Methodology for measuring health-state preferences. II. Scaling methods. J Clin Epidemiol 1989;42:459-71.
2. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life [review]. Ann Intern Med 1993;118:622-9.
3. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-28.
4. Teng YK, Verburg RJ, Sont JK, van den Hout WB, Breedveld FC, van Laar JM. Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. Arthritis Rheum 2005;52:2272-6.
5. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
6. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
7. Ware JE, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's manual. Boston: Quality Metric; 1994.
8. Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006;33:681-9.
9. Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
10. Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-44.
11. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82.
12. Feeny D, Wu L, Eng K. Comparing short form 6D, standard gamble, and Health Utilities Index Mark 2 and Mark 3 utility scores: results from total hip arthroplasty patients. Qual Life Res 2004;13:1659-70.
13. Cranney AB, Coyle D, Hopman WM, Hum V, Power B, Tugwell PS. Prospective evaluation of preferences and quality of life in women with hip fractures. J Rheumatol 2005;32:2393-9.
14. Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006;23:1629-35.
15. Wee HL, Li SC, Cheung YB, Fong KY, Thumboo J. The influence of ethnicity on health-related quality of life in diabetes mellitus: a population-based, multiethnic study. J Diabetes Complications 2006;20:170-8.
16. Alarcon GS, McGwin G Jr, Uribe A, Friedman AW, Roseman JM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004;51:465-74.
17. Strand V. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Lupus 2004;13:406-11.
18. Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. Rheumatology (Oxford) 2005;44:751-5.
19. Abu-Shakra M, Keren A, Livshitz I, Delbar V, Bolotin A, Sukenik S, et al. Sense of coherence and its impact on quality of life of patients with systemic lupus erythematosus. Lupus 2006;15:32-7.
20. Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2007;26:24-9. E-pub ahead of print 2006. URL: http://www.springerlink. com/content/a634033p4n45q782.
21. Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol 2001;28:525-32.
22. Friedman AW, Alarcon GS, McGwin G Jr, Straaton KV, Roseman J, Goel N, et al. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. Arthritis Care Res 1999;12:256-66.
23. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999;8:197-209.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
25. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72.
26. Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
27. US Department of Commerce, Bureau of the Census. Current population reports, Series P-23, No. 28 and Series P-60, No. 68 and subsequent years. Washington, DC: Housing and Household Economic Statistics Division; 1995.
28. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
29. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
30. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
31. Fernandez M, Alarcon GS, Calvo Alen J, Andrade R, McGwin G Jr, Vila LM, for the LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007;57:576-84.
32. Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001;44:2797-806.
33. Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic group. VII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001;45:191-202.
34. Alarcon GS, Roseman J, Bartolucci AA, Friedman AW, Moulds JM, Goel N, et al. Systemic lupus erythematosus in three ethnic groups. II. Features predictive of disease activity early in its course. Arthritis Rheum 1998;41:1173-80.
35. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
36. Toloza SM, Roseman JM, Alarcon GS, McGwin G Jr, Uribe AG, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004;50:3177-86.
37. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-84.
38. Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005;14:1169-89.
39. Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2005;43:1580-6.
40. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002;61:409-13.
41. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50.
42. Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore) 2005;84:218-24.
43. Walsh SJ, DeChello LM. Geographical variation in mortality from systemic lupus erythematosus in the United States. Lupus 2001;10:637-46.
44. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
45. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, et al. Randomized clinical trials and longitudinal observation studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999;26:504-7.
46. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2000;9:322-7.
47. National Institutes of Health. Aspreva lupus management study (ALMS). URL: http://www.clinicaltrials.gov/ct/gui/show/NCT0012082?order=6.
48. National Institutes of Health. A study to evaluate the efficacy and safety of rituximab in patients with severe systemic lupus erythematosus (SLE). URL: http://www.clinicaltrials.gov/ct/show/NCT00137969?order=2.